What Will Redefine Pathology in 2026? - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

What Will Redefine Pathology in 2026?

Industry leaders outline how computational modeling and large-scale sequencing will reshape discovery, diagnostics, and clinical development in 2026 and beyond

  • By

  • Jessica Allerton

  • January 14, 2026

  • 7 min

Share

  • 1

    In 2026, AI will evolve from a time-saving tool to a critical component in research and development, aiding in hypothesis generation and experiment design.

  • 2

    The success in slowing Huntington's disease will drive increased research into other repeat expansion disorders, necessitating broader use of long-read sequencing.

  • 3

    More nations will invest in population-specific genomic projects, enhancing precision medicine and addressing the genetic diversity gap in healthcare.

  • 4

    AI-guided platforms will transform early biologics pipelines by merging diverse datasets to identify disease targets more effectively and efficiently.

  • 5

    Digital twins are expected to become mainstream in clinical development, supported by evolving regulatory frameworks and a focus on patient-centric trials.

Original Source(s)

What Will Redefine Pathology in 2026?

  • by Jessica Allerton

  • January 14, 2026

Related Content

The MIC-Outcome Gap Explained 

Single-cell imaging of 140 million bacteria reveals drug tolerance—not just resistance—drives mycobacterial treatment outcomes

Nodular Fasciitis May Mimic Sarcoma

Molecular testing may help avoid overtreatment when benign soft-tissue tumors present with atypical clinical or histologic features.

FDA Approves Expanded Liquid Biopsy Panel

Updated liquid biopsy combines genomic and epigenomic profiling for companion diagnostic use across multiple tumor types.